SK bioscience and Sanofi plan global Phase III trials for their 21-valent pneumococcal conjugate vaccine candidate, GBP410, in over 7,700 subjects aged six weeks to 17 years.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
SK bioscience and Sanofi's GBP410 vaccine enters global Phase III trials
